These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30985927)

  • 1. Is there still a role for stem cell transplantation in multiple myeloma?
    Mina R; Lonial S
    Cancer; 2019 Aug; 125(15):2534-2543. PubMed ID: 30985927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.
    Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; San Miguel J; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2039-2051. PubMed ID: 26428082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.
    Gonsalves WI; Buadi FK; Ailawadhi S; Bergsagel PL; Chanan Khan AA; Dingli D; Dispenzieri A; Fonseca R; Hayman SR; Kapoor P; Kourelis TV; Lacy MQ; Larsen JT; Muchtar E; Reeder CB; Sher T; Stewart AK; Warsame R; Go RS; Kyle RA; Leung N; Lin Y; Lust JA; Russell SJ; Zeldenrust SR; Fonder AL; Hwa YL; Hobbs MA; Mayo AA; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA; Roy V
    Bone Marrow Transplant; 2019 Mar; 54(3):353-367. PubMed ID: 29988062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment for patients with newly diagnosed multiple myeloma in 2015.
    Mateos MV; Ocio EM; Paiva B; Rosiñol L; Martínez-López J; Bladé J; Lahuerta JJ; García-Sanz R; San Miguel JF
    Blood Rev; 2015 Nov; 29(6):387-403. PubMed ID: 26094881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stem-cell transplantation in multiple myeloma.
    Harousseau JL; Moreau P; Attal M; Facon T; Avet-Loiseau H
    Best Pract Res Clin Haematol; 2005; 18(4):603-18. PubMed ID: 16026740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.
    Garderet L; Iacobelli S; Koster L; Goldschmidt H; Johansson JE; Bourhis JH; Krejci M; Leleu X; Potter M; Blaise D; Koenecke C; Peschel C; Radocha J; Metzner B; Lenain P; Schäfer-Eckart K; Pohlreich D; Grasso M; Caillot D; Einsele H; Ladetto M; Schönland S; Kröger N
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1372-1378. PubMed ID: 29408334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
    Nishihori T; Alsina M
    Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
    Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tandem stem cell transplantation for multiple myeloma patients.
    Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F
    Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
    Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D; Li J; Huang BH; Liu JR; Zou WY; Su C
    Chin Med J (Engl); 2012 Dec; 125(24):4454-9. PubMed ID: 23253719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
    Kazandjian D; Landgren O
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):559-568. PubMed ID: 31730582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well.
    Martino M; Morabito F
    Expert Opin Biol Ther; 2015 Feb; 15(2):149-54. PubMed ID: 25435056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of relapsed multiple myeloma after autologous stem cell transplant.
    Holstein SA; Richardson PG; Laubach JP; McCarthy PL
    Biol Blood Marrow Transplant; 2015 May; 21(5):793-8. PubMed ID: 25652690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma.
    Ali MO; Al Hadidi S
    Transplant Cell Ther; 2022 Sep; 28(9):572-580. PubMed ID: 35750284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
    Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
    Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.